Excerpt: We analyze the effects on consumers of an extreme policy experiment-- 'Napsterizing' pharmaceuticals-- whereby all patent rights on branded prescription drugs are eliminated for both existing and future prescription drugs ... [P]roviding greater access to the current stock of prescription drugs yields large benefits to existing consumers. However, realizing those benefits has a substantially greater cost in terms of lost consumer benefits from reductions in the flow of new drugs.